Sapropterin (Kuvan): Synthetic form of tetrahydrobiopterin approved for the treatment of PKU
Article
FDA approved sapropterin on December 13, 2007, to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due ro BH4-responsive phenylketonuria (PKU).